Anastrozole and Pitavastatin Interaction: Avoid | Peptide Database

Meldonium is increasingly used in the performance enhancement community as an adjunctive agent to protect the heart during anabolic steroid cycles. Supraphysiological androgen use is associated with left ventricular hypertrophy, impaired diastolic function, reduced ejection fraction, and accelerated atherosclerosis. Meldonium's ability to optimize cardiac energy metabolism and reduce toxic lipid intermediates may mitigate some of these effects, though direct clinical evidence in this specific context is limited to anecdotal and observational data. By shifting fuel utilization from fatty acids toward glucose, meldonium may improve aerobic efficiency under submaximal exercise conditions. Athletes in Eastern European countries have used meldonium for decades to support training capacity and recovery. The metabolic shift may spare glycogen during prolonged activity and reduce post-exercise oxidative stress. This use drove WADA's decision to ban the substance. In Baltic states and Russia, meldonium is an approved prescription drug for the treatment of stable angina pectoris and chronic ischemic heart disease. Clinical trials conducted primarily in Latvia and Russia have demonstrated reductions in angina frequency, improved exercise tolerance on treadmill testing, and reduced nitroglycerin consumption when meldonium is added to standard antianginal therapy. Meldonium has been investigated as an adjunctive therapy in chronic heart failure, where impaired cardiac energy metabolism contributes to disease progression. Small trials have reported improvements in exercise capacity and quality-of-life scores when meldonium was added to standard heart failure regimens. Larger-scale, Western-standard randomized controlled trials are lacking. The drug is prescribed in some Eastern European countries for acute and chronic cerebrovascular insufficiency. Its vasodilatory effects via nitric oxide stimulation and metabolic optimization may offer neuroprotective benefits during ischemic events. Evidence is primarily from non-Western clinical trials.

LGD-4033 is widely regarded as the most potent SARM for lean mass accrual. In the Phase 2 VK5211 trial in hip fracture patients, subjects receiving 1 mg/day gained an average of 1.21 kg of lean body mass over 12 weeks. Higher doses in healthy volunteer studies have shown even greater lean mass increases. Users consistently report LGD-4033 as superior to Ostarine for mass-building purposes. Clinical trial data demonstrated statistically significant improvements in leg press strength in hip fracture patients treated with LGD-4033. Anecdotal reports consistently describe notable strength increases within 3-4 weeks, particularly in compound movements. Strength gains are dose-dependent. The anabolic activity of LGD-4033 without estrogenic water retention makes it suitable for simultaneous lean mass gain and fat reduction. Some water retention can occur due to the compound itself (non-estrogenic mechanism), but overall body composition changes favor a recomposition effect. Clinical data shows favorable shifts in lean-to-fat mass ratio. Viking Therapeutics conducted a Phase 2 trial (VK5211) evaluating LGD-4033 in patients recovering from hip fracture surgery. The trial met its primary endpoint, demonstrating dose-dependent increases in lean body mass at 12 weeks. Secondary endpoints including leg press strength and stair-climbing speed also showed statistically significant improvements versus placebo. Originally developed for conditions involving muscle wasting and age-related muscle loss. Preclinical and early clinical data support the potential to preserve or restore muscle mass in catabolic states. The hip fracture trial results are directly relevant to sarcopenia and frailty in elderly populations. Preclinical data demonstrates that LGD-4033 increases bone mineral density and bone formation markers through direct AR-mediated signaling in osteoblasts. While no dedicated human trial has been completed for this indication, the mechanism supports potential utility in osteoporosis, particularly in populations where traditional androgen therapy is contraindicated.